Parameter | B | Std. Error | 95% Confidence Interval | p-value* | ||
---|---|---|---|---|---|---|
Lower | Upper | |||||
(Intercept) | 0.500 | 0.038 | 0.426 | 0.574 | 0.000 | |
Age | -0.002 | 0.000 | -0.003 | -0.001 | 0.000 | |
Hospital Days | -0.003 | 0.002 | -0.006 | 0.000 | 0.060 | |
Type of Hospital (Reference - Public) | Semi-private | 0.231 | 0.016 | 0.200 | 0.263 | 0.000 |
Education (Refernce- No Education) | Primary & Middle | 0.031 | 0.020 | -0.009 | 0.071 | 0.133 |
Up to Senior Secondary | 0.031 | 0.021 | -0.009 | 0.072 | 0.128 | |
 | Graduation & above | 0.075 | 0.023 | 0.030 | 0.120 | 0.001 |
Type of Cancer (Reference-Solid) | Haematological | -0.033 | 0.027 | -0.086 | 0.020 | 0.218 |
Type of Treatment (Reference- Chemotherapy) | Radiotherapy | -0.025 | 0.033 | -0.090 | 0.039 | 0.440 |
Palliative care | -0.258 | 0.056 | -0.367 | -0.149 | 0.000 | |
Surgery | -0.127 | 0.033 | -0.192 | -0.062 | 0.000 | |
Combination Therapy** | -0.133 | 0.024 | -0.181 | -0.085 | 0.000 | |
Maintenance Therapy | -0.702 | 0.151 | -0.998 | -0.406 | 0.000 | |
On diagnostic workup | -0.144 | 0.037 | -0.216 | -0.072 | 0.000 | |
Hormone Therapy | -0.163 | 0.184 | -0.523 | 0.198 | 0.377 | |
Immunotherapy | 0.098 | 0.062 | -0.022 | 0.219 | 0.110 | |
Others (clinical follow up) | -0.136 | 0.029 | -0.193 | -0.080 | 0.000 | |
Line of Treatment (Reference - First Line) | Second Line | -0.065 | 0.025 | -0.114 | -0.017 | 0.008 |
Third Line | 0.037 | 0.062 | -0.084 | 0.158 | 0.550 | |
Fourth Line | 0.117 | 0.104 | -0.086 | 0.321 | 0.258 | |
Response to Treatment (Reference– Disease free survival) | Progressive | -0.149 | 0.040 | -0.227 | -0.071 | 0.000 |
Ongoing | 0.016 | 0.024 | -0.031 | 0.064 | 0.504 | |
Adverse Effect (Reference - With Adverse Effect) | Without Adverse Effect | 0.085 | 0.025 | 0.037 | 0.133 | 0.001 |